Pediatric Infectious Disease Journal:
OTITIS MEDIA FORUM: PROCEEDING FROM A SYMPOSIUM HELD ON SEPTEMBER 23 TO 25, 1999 IN CARMEL, CA: Clinical and Epidemiologic Aspects of Acute Otitis Media
Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms
DAGAN, RON MD; LEIBOVITZ, EUGENE MD; LEIBERMAN, ALBERTO MD; YAGUPSKY, PABLO MD
Section Editor(s): Dagan, Ron M.D.
From the Pediatric Infectious Disease Unit (RD, EL), Otolaryngology Department (AL) and Clinical Microbiology Laboratories (PY), Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Address for reprints: Ron Dagan, M.D., Director, Pediatric Infectious Disease Unit, Soroka University Medical Center, P.O. Box 151, Beer-Sheva 84101, Israel. Fax 972-7-623-2334; E-mail firstname.lastname@example.org.
Acute otitis media (AOM) is the most common cause of antibiotic prescription in children in the developed world. In the presence of increasing resistance among the pathogens causing AOM, it is important to attempt to answer two related questions with regard to antibiotic treatment: Does the increasing antibiotic resistance among AOM pathogens cause an increase in bacteriologic and clinical failure rate? Does the use of antibiotics promote the carriage and spread of antibiotic-resistant pathogens? Those two questions differ significantly. The first addresses the issue of the impact of resistance on the individual, whereas the latter addresses the antibiotic effect of the treatment on the society as a whole.
CLINICAL SIGNIFICANCE OF ANTIBIOTIC RESISTANCE IN AOM
The role of antibiotic treatment of AOM is to sterilize the middle ear cavity of fluid and pathogens. To achieve this goal, therapeutic concentrations of the drug in the middle ear fluid (MEF) must be reached.
Antibiotics vary in their type of interaction with the pathogens. Most drugs used for the treatment of AOM belong to the beta-lactam and macrolide classes. These drugs act by a time-dependent killing mechanism; i.e. they must reach concentrations in the MEF that are above the MIC of the pathogens and remain above this concentration for at least 40 to 50% of the dosing interval. 1, 2 The same mechanism applies for antibiotics from other classes, such as clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX). Other classes, such as the azalides (to which azithromycin belongs), quinolones (including the newer quinolones, which are also future candidates for the treatment of pediatric infections and are active against pneumococci) and the aminoglycosides, act by a concentration killing mechanism; i.e. killing of bacteria does not depend simply on the time above MIC but rather depends on the ratio between the peak concentration achieved in the MEF and the MIC of the pathogen or the ratio of the area under the concentration curve over the MIC of the pathogen. 1, 2
The increase in the prevalence of antibiotic resistance among Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, the three main pathogens of AOM, was described in detail elsewhere in this supplement and is reflected in the increasing MICs of the common drugs to these AOM pathogens. 3
In southern Israel, an alarming increase in antibiotic resistance was observed among middle ear pneumococcal isolates during the last decade (R Dagan, M.D., unpublished data, 1999) (Fig. 1). Only 15% of the strains were nonsusceptible to penicillin (penicillin MIC >0.1 μg/ml) in 1992, but 58% were nonsusceptible to penicillin in 1998; the resistance to macrolides (which in Israel was also associated with resistance to clindamycin in most strains) rose from 2% to ∼10%, and the resistance to TMP-SMX rose from 13% to >40%. Furthermore the resistance to the three antibiotic classes (defined as multiresistant S. pneumoniae) rose from only 1% to 14%. In addition during recent years the prevalence of H. influenzae isolates causing AOM that produce beta-lactamase was ∼20%, and all M. catarrhalis causing AOM were beta-lactamase producers in our region. The resistance of H. influenzae to TMP-SMX is now ∼30%.
Because the ability of an antibiotic drug to eradicate the pathogens depends on the relation of its concentration at the site of infection to the MIC of the pathogen, it is clear that the increasing MIC values observed today may impair bacteriologic eradication. Appropriate demonstration of this phenomenon can be achieved by performing randomized comparative trials in which a MEF culture is performed by tympanocentesis immediately before antibiotic administration and a second culture is obtained during the course of treatment. 4 Howie and Ploussard 5 introduced this method and named it the in vivo sensitivity test. The advantage of this double tympanocentesis method is that with relatively few enrolled subjects, it can determine bacteriologic failure rates with various drugs for antibiotic-susceptible and -resistant organisms and predict clinical efficacy. 4, 6–14
There is now solid evidence that the increasing antibiotic resistance among isolates of S. pneumoniae is associated with a decreased ability of many drugs to eradicate the pathogens in AOM. Our group in 1996 provided the first evidence that increasing resistance among S. pneumoniae may affect bacteriologic outcome in AOM. 12 We demonstrated a clear correlation between penicillin and cephalosporin MIC values of the drugs to the organism and the ability of oral cephalosporins to eradicate the pneumococci from the MEF. In this study children were treated with cefaclor or cefuroxime-axetil for AOM. When the otitis media (OM) was caused by penicillin-susceptible S. pneumoniae (MIC < 0.1 μg/ml), eradication of the organisms by both cefuroxime-axetil and cefaclor could be demonstrated after 3 to 4 days of treatment in >90% of the cases. However, when MIC increased to 0.125 to 0.25 μg/ml (low range of penicillin-intermediately resistant S. pneumoniae), the eradication rate dropped to 57% for cefaclor; when penicillin MIC was 0.38 to 1.0 μg/ml (high rage of penicillin-intermediately resistant S. pneumoniae), the eradication rate dropped to 20% for cefaclor. Even for cefuroxime-axetil, which is considered a more potent drug than cefaclor against S. pneumoniae, the eradication rate dropped to 50% when the penicillin MIC values ranged from 0.38 to 1.0 μg/ml.
Further studies performed on pneumococcal AOM showed that there is presently a difficulty in eradicating S. pneumoniae from MEF and that this is related to the increasing resistance (R Dagan, M.D., unpublished data, 1999;Fig. 2). 7, 11, 12 In these studies, of 248 children receiving beta-lactam drugs for AOM, in 146 (59%) pneumococci were nonsusceptible to penicillin. The overall success of the beta-lactam antibiotic drugs with penicillin-susceptible organisms was 92% compared with only 72% for those infected with penicillin-nonsusceptible pneumococci. Furthermore 2 approved regimens for AOM in the US, namely cefaclor 40 mg/kg/day for 10 days and a single dose of intramuscular ceftriaxone 50 mg/kg/day did not perform much better than placebo for penicillin-nonsusceptible strains.
We studied also two non-beta-lactam antimicrobial drugs, azithromycin and TMP-SMX. For these drugs, unlike the beta-lactam drugs, most of the nonsusceptible pneumococci are highly resistant. The failure rates associated with resistance were therefore even more striking (Fig. 2). When the organisms were susceptible to the administered drug the success rate was close to 100%, but when the organisms were resistant the two drugs did not perform better than placebo.
Overall of the 324 patients presented in Figure 2, 172 of 324 (53%) had altered susceptibility to the administered drugs, resulting in an increase of failure rate from 10 of 152 (7%) among those infected with susceptible organism (the picture that prevailed in the preantibiotic resistance era of S. pneumoniae) to 63 of 172 (37%) among those infected with S. pneumoniae with altered susceptibility. This has an important implication because >95% of the prescribed antibiotic courses for AOM presently are with drugs belonging to the classes represented by Figure 2. Therefore it is not surprising that a recent report by the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group of the Centers for Disease Control and Prevention has concluded that “the management of otitis media has entered a new era with the development of drug resistant S. pneumoniae.”19
Although the situation with H. influenzae is not as alarming as with S. pneumoniae, beta-lactamase production and resistance to TMP-SMX is increasing. Convincing evidence that beta-lactamase production by H. influenzae may be an important factor to be taken into consideration in the treatment of AOM is derived from a series of studies in the US and Israel (Fig. 3). 13–18 The bacteriologic response to amoxicillin when AOM is caused by beta-lactamase-producing H. influenzae after 2 to 7 days was similar to that observed with placebo, whereas higher eradication rates were obtained when H. influenzae did not produce beta-lactamase.
We also understand now that some drugs, such as cefaclor and the new macrolides (e.g. clarithromycin, azithromycin) may not be as effective against H. influenzae as believed despite their in vitro activity, because of their unfavorable pharmacodynamic properties. 1, 3 This results in the conclusion that the current therapeutic arsenal against H. influenzae is far from being satisfactory. Results from recent double tympanocentesis studies in southern Israel, with 392 cases of H. influenzae AOM are shown in Figure 4. 12, 13, 15–17, 19 Most drugs in these studies were associated with a relative high failure rate. The only exception was intramuscular ceftriaxone, which reaches concentrations greater than the MIC of the drug to the organism for >24 h after injection. 20 The eradication rate of H. influenzae with ceftriaxone was 100%, regardless of whether the drug was given as a single dose or for 3 successive days. In contrast the effectiveness of cefaclor and azithromycin is clearly in the range of that of placebo in their ability to eradicate H. influenzae within 3 to 4 days of treatment. Evidence that another new macrolide often prescribed for AOM, namely clarithromycin, is similar to azithromycin in its effect on H. influenzae is provided in the literature. 21
The data presented above show that the increasing antibiotic resistance affects significantly our ability to rapidly eradicate the organisms from the MEF during episodes of AOM by commonly used antibiotics. However, does this finding imply that the clinical outcome is also affected? In AOM spontaneous clinical recovery is observed in >70% of the cases; it is therefore difficult to answer this question because under these circumstances a drug with minimal antibacterial activity will appear to be almost as effective as a highly efficacious drug. This phenomenon was termed the “Pollyanna phenomenon” by Marchant et al. 4 after the blindly optimistic heroine of the novel Pollyanna by E. H. Porter. As a result it is not easy to appreciate the clinical implication of the increase in bacteriologic failures.
In a retrospective study Carlin et al. 22 concluded that most cases of clinical failure in AOM were associated with bacteriologic failure, but that these 2 outcomes were frequently discordant. In a prospective study we investigated the relationship between the bacteriologic outcome 72 to 96 h after initiation of treatment and the clinical outcome. 23 In that study we studied 123 infants and children with AOM treated with various antibiotics. After 72 to 96 h the MEF culture was still positive in 57 children. Of the 66 children with culture-negative middle ear fluid, 2 (3%) experienced clinical failure vs. 21 (37%) of the 57 with culture-positive MEF (Fig. 5). 23 In other words although 63% of the patients recovered clinically despite persistence of the middle ear fluid organisms, 21 of the 23 of all cases of clinical failure (91%) occurred in those in whom the organism was not eradicated at the time of the second tympanocentesis. Because only about one-third of those with bacteriologic failure experience clinical failure, the increment of clinical failures caused by increasing antibiotic resistance can be inconspicuous. We may therefore witness only a small increase in failure rate each year when clinical outcome is used to measure drug efficacy. However, in a country like the United States, where >20 000 000 episodes of AOM occur yearly, an increment as small as 1% may represent an increase of >200 000 cases of clinical failure yearly. 24
IMPLICATION OF ANTIBIOTIC TREATMENT ON CARRIAGE AND SPREAD OF RESISTANT ORGANISMS
When an antibiotic drug is administered for AOM, we are targeting the MEF. However, the drug is absorbed and distributed to all compartments of the body. These include areas that harbor the normal flora of the body, such as the naso- and oropharynx, mouth, skin, the intestine and the genital tract. Once the antibiotic drug reaches these parts of the body, it rapidly eliminates or reduces the concentration of the organisms that are susceptible to the drug. A rapid replacement occurs with either the already existing organism that is more resistant to the drug or by a newly acquired resistant organism. This article focuses on the impact of antibiotic administration on S. pneumoniae carried in the nasopharynx, although most of the considerations apply to many other species colonizing the body.
It is established that acquisition and carriage of S. pneumoniae may be associated with the occurrence of AOM, 25–27 bacteremia 28–31 and pneumonia. 32 Therefore the study of carriage of this pathogen and the influence of antibiotic treatment on the carriage rate and transmission is important.
Most children are often colonized with S. pneumoniae during the first years of life. This colonization may be detected in early infancy, peaking toward the 2nd to the 3rd year of life. 33, 34 In the developing world colonization can be as high as 60% or greater by 2 months of age. 35, 36 In the more developed, less crowded populations, the carriage is lower and can be as low as 15% for those younger than 3 months of age. 31, 37–41
During acute viral infection, nasopharyngeal carriage rate of S. pneumoniae and other otitis pathogens increases. Epidemiologic and animal studies suggest that this colonization predisposes the development of pneumococcal AOM. 26, 27, 42–47
Similar to the effect on the MEF not all antibiotic drugs act equally on S. pneumoniae residing in the nasopharynx. We may expect that drugs with a higher penetration to the nasopharynx and higher in vitro activity against the organisms will achieve a better eradication than those with less favorable pharmacodynamic properties. Similarly we may expect S. pneumoniae with higher MIC to the administered drug to be eradicated less successfully.
Antibiotic use has been shown to be associated with nasopharyngeal carriage of antibiotic-resistant S. pneumoniae on numerous occasions. 27, 41, 48–51 Leach et al. 52 showed prolonged carriage of azithromycin-resistant S. pneumoniae after a single dose of azithromycin administered to Australian aboriginals for the treatment of trachoma. Brook and Gober 53 showed that prophylaxis with amoxicillin increased the carriage of penicillin-resistant S. pneumoniae. Abdel-Haq et al. 54 demonstrated recently an association between TMP-SMX prophylaxis and nasopharyngeal colonization with both TMP-SMX and penicillin-resistant S. pneumoniae.
A series of new studies was able to reveal some of the early processes that occur in the nasopharynx during and in the immediate posttreatment period in cases of AOM, with regard to antibiotic-resistant S. pneumoniae. In a prospective study Dabernat et al. 55 (Fig. 6) compared two antibiotics widely used for AOM, cefixime and amoxicillin/clavulanate. Cefixime is an oral third generation cephalosporin with weak in vitro activity against S. pneumoniae in general and against penicillin-nonsusceptible S. pneumoniae, in particular. Amoxicillin/clavulanate is a much more potent drug against those organisms. The study demonstrated that cefixime did not reduce significantly the carriage of S. pneumoniae, whereas amoxicillin-clavulanate reduced significantly the carriage of both penicillin-susceptible and nonsusceptible S. pneumoniae. Only after 1 month did the effect of the two drugs tend to equalize, still with a trend for higher carriage of penicillin-resistant S. pneumoniae among the cefixime recipients.
The observation that a differential action on pneumococcal nasopharyngeal carriage depends on the drug and the prevalent strains of S. pneumoniae in the community was further substantiated by several additional prospective studies. 55–59 The data in Table 1 demonstrate several points: (1) most studied drugs (i.e. amoxicillin/clavulanate, cefpodoxime, cefuroxime- axetil, azithromycin and TMP-SMX) had a substantial effect on the nasopharynx and were able to eradicate or to reduce the carriage of pneumococci that were susceptible to the drugs; (2) for all drugs only little if any effect was seen when the organism had reduced susceptibility to the administered drug; (3) some drugs, such as azithromycin and TMP-SMX, appeared not only to reduce colonization with resistant S. pneumoniae but even to promote it; (4) the beta-lactam drugs with higher activity against S. pneumoniae in general and penicillin-nonsusceptible S. pneumoniae in particular (i.e. amoxicillin/clavulanate, cefuroxime-axetil) had a stronger effect on S. pneumoniae colonization than did the weaker drugs (i.e. cefaclor, cefpodoxime, cefixime); and (5) the effect on the nasopharyngeal colonization was rapid and was observed after only 3 to 4 days of treatment.
Even more intriguing than the differential effect of various drugs on the carriage of S. pneumoniae is their ability to alter the nasopharyngeal colonization by selecting new pneumococcal strains either by overgrowth of strains that were masked by other organisms or that were rapidly acquired after initiation of treatment.
Leach et al. 52 administered 1 dose of azithromycin to children with trachoma and followed them for S. pneumoniae nasopharyngeal carriage. Before treatment 68% were colonized, but only 1% had azithromycin-resistant S. pneumoniae. Two to 3 weeks later the total colonization rate decreased to 29%, but 16% were colonized with azithromycin-resistant S. pneumoniae. Two months later 78% were colonized with S. pneumoniae and 27% had azithromycin-resistant S. pneumoniae. Only 6 months after drug administration the pneumococcal colonization rate and the prevalence of azithromycin-resistant organisms were similar to the initial ones.
In a prospective study we showed that in 19 of 120 (16%) patients treated with various antibiotics for AOM, a new S. pneumoniae isolate was recovered from the nasopharynx after only 3 to 4 days of treatment, and 16 of those 19 strains (84%) were resistant to the administered drug. 58 Cohen et al. 56 showed that among 94 children treated with either amoxicillin/clavulanate or cefpodoxime-proxetil, carrying S. pneumoniae at the end of treatment, 22 did not harbor pneumococci beforehand and 16 carried another genotypically different serotype compared with the initial S. pneumoniae nasopharyngeal isolate. In another prospective study Cohen et al. 57 showed that 38 of 230 (17%) and 13 of 235 (5%) of those treated with a single dose of ceftriaxone and a 10-day regimen of high dose amoxicillin/clavulanate, respectively, acquired a new pneumococcal isolate by the end of treatment (Days 12 to 14). Of those new isolates 66 and 62% were penicillin-nonsusceptible.
In a recent study we observed an impressive emergence of new pneumococcal serotypes resistant to the drugs for AOM (Fig. 7). 59 When cultures obtained during treatment and immediately after treatment were combined, new serotypes, either susceptible or resistant to the treatment drug, appeared in 21, 24 and 31% of those treated with azithromycin, amoxicillin/clavulanate and TMP-SMX, respectively. The combined appearance of new resistant pneumococci to the respective drugs was 15, 8 and 27%, respectively.
It is clear that one of the serious problems among the prevalent pneumococcal strains is the emerging resistance to more than one antibiotic drug classes. 3 This phenomenon can explain why in various circumstances the use of one antibiotic may now be related to induction of carriage with S. pneumoniae that is resistant not only to the antibiotic to which it was exposed but also to other classes of antibiotics. The first example was provided by Arason et al. 51 from Iceland. In 1993 about one-fifth of the pneumococcal strains in Iceland were penicillin-nonsusceptible and 80% of them were multidrug-resistant. Thus it was not surprising that when the risks for the carriage of penicillin-resistant S. pneumoniae were investigated, a clear association was not only found with beta-lactam use, but also with that of TMP-SMX and erythromycin (Fig. 8). 51 Other authors have also shown an association between TMP-SMX consumption and carriage of penicillin-resistant S. pneumoniae. 39, 60
In a recent study a group of children with either negative nasopharyngeal culture for S. pneumoniae or positive culture yielding TMP-SMX-susceptible S. pneumoniae was studied longitudinally during TMP-SMX treatment for AOM. 59 The carriage of TMP-SMX-resistant S. pneumoniae increased from none on Day 1 to 23, 28 and 33% on Days 4 to 6, 12 to 14 and 21 to 40, respectively. The respective figures for penicillin-nonsusceptible S. pneumoniae were 4, 26, 31 and 43%, respectively. This remarkable induction of penicillin-resistant nasopharyngeal colonization by TMP-SMX treatment was caused by the linkage between penicillin and TMP-SMX resistance.
The dramatic changes occurring in the nasopharynx after initiation of antibiotics has two important consequences. First the phenomenon described above predisposes patients to new infections with more resistant organisms, as can be demonstrated both retrospectively and prospectively. We recently examined the association of antibiotic resistance in 837 MEF pneumococcal isolates in AOM with previous antibiotic use (Fig. 9). 61 Penicillin resistance increased as the timing of the culture became closer to the previous antibiotic treatment. In a prospective study we were able to show that antibiotic treatment with various drugs could not only increase nasopharyngeal carriage of antibiotic-resistant S. pneumoniae but could even induce superinfection of the middle ear fluid within 3 to 5 days if the initial nasopharynx harbored a strain of S. pneumoniae that was resistant to the administered drug. 62 Second increasing the prevalence of antibiotic-resistant S. pneumoniae in the nasopharynx may increase transmission to other close contacts, especially infants and young children in crowded conditions such as in extended families and day-care centers. 41, 63–69
Thus the widespread use of antibiotics for AOM in the era of prevalent resistance not only is associated with reduced bacteriologic and clinical responses in individual patients but also increases nasopharyngeal carriage of resistant organisms, which in turn facilitates their spread to others in the society, especially to the age group in which AOM is most prevalent. This creates a vicious cycle that is difficult, if not impossible, to overcome (Fig. 10). The presence of such a vicious cycle poses a real challenge to society, and innovative approaches must be tested to reduce this phenomenon. Efforts should be made to reduce antibiotic use, to study the possibilities of preventing colonization by various nonantibiotic substances and to study new vaccines against pathogens predisposing or causing AOM.
Question: What happens to clinical failures with resistant organisms?
Dr. Dagan: We call clinical failure a switch in antibiotic treatment because the patient is not responding. When we change we usually change to ceftriaxone. There are usually few failures after 3 days of ceftriaxone. If they do fail we repeat the ceftriaxone for another 3 days. If that fails we look at the bacteriology.
Question: Is there any characteristic that defines those patients who are persistent clinical failures?
Dr. Dagan: The younger the patient population the more likely there will be more clinical failures. Also over one-third of the children in the study had previous OM and over one-third were previously treated with antibiotics.
Question: A study with ofloxacin demonstrated in children with ear tubes that topical delivery through the tubes was superior in eradicating AOM than was systemic amoxicillin/clavulanate. Would the antibiotic resistance problem be reduced if there was a way to deliver antibiotics only to the middle ear?
Dr. Dagan: You most likely need to get the antibiotic to the mucosa. There is uncertainty that there will be a high enough concentration by diffusion.
1. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15:255–9.
2. Craig WA. Pharmacokinetics/pharmacodynamics parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 16:1–12.
3. Jacobs MR. Increasing antibiotic resistance among acute otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters. Pediatr Infect Dis J 2000; 19(Suppl)S47–56.
4. Marchant CD, Carlin SA, Johnson CE, Shurin PA. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the “Pollyanna phenomenon.” J Pediatr 1992; 120:72–7.
5. Howie VM, Ploussard JH. The “in vivo
sensitivity test”: bacteriology of middle ear exudate. Pediatrics 1969; 44:940–4.
6. Howie VM, Dillard R, Lawrence B. In vivo
sensitivity test in otitis media: efficacy of antibiotics. Pediatrics 1985; 75:8–13.
7. Howie VM, Ploussard JH. Efficacy of fixed combination antibiotics versus
separate components in otitis media. Clin Pediatr 1972; 11:205–14.
8. Marchant CD, Shurin PA, Turcyzk VA, et al. A randomized controlled trial of cefaclor compared with trimethoprim-sulfamethoxazole for treatment of acute otitis media. J Pediatr 1984; 105:633–8.
9. Marchant CD, Shurin PA, Johnson CE, et al. A randomized controlled trial of amoxicillin plus clavulanate compared with cefaclor for treatment of acute otitis media. J Pediatr 1986; 109:891–6.
10. Johnson CE, Carlin SA, Super DM, et al. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991; 119:117–22.
11. Howie VM, Owen MJ. Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media. Pediatr Infect Dis J 1987; 6:989–91.
12. Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J 1996; 15:980–5.
13. Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997; 176:1253–9.
14. Dagan R. Can the choice of antibiotics for therapy of acute otitis media be logical? Eur J Clin Microbiol Infect Dis 1998; 17:1–5.
15. Dagan R, Piglansky L, Yagupsky P, Fliss DM, Leiberman A, Leibovitz E. Bacteriologic response in acute otitis media: comparison between azithromycin, cefaclor and amoxicillin [Abstract K-103]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada, September 28 to October 1, 1997. Washington, DC: American Society for Microbiology, 1997.
16. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic efficacy of 3-days intramuscular ceftriaxone in non-responsive acute otitis media [Abstract. K-105]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28 to October 1, 1997. Washington, DC: American Society for Microbiology, 1997.
17. Leibovitz E, Piglansky L, Raiz S, et al. The bacteriologic efficacy of 1-day versus
3-day intramuscular ceftriaxone in the treatment of non-responsive acute otitis media [Abstract M-039]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 24 to 27, 1998. Washington, DC: American Society for Microbiology, 1998.
18. Leibovitz E, Dagan R, Piglansky L, et al. The bacteriologic and clinical efficacy of trimethoprim/sulfamethoxazole in the treatment of acute otitis media [Abstract 778]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26 to 29, 1999. Washington, DC: American Society for Microbiology, 1999.
19. Dowell SF, Butler JC, Giebink S, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-resistant Streptococcus pneumoniae
Therapeutic Working Group. Pediatr Infect Dis J 1999; 18:1–19.
20. Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson KG. Penetration of ceftriaxone into the middle ear fluid of children. Pediatr Infect Dis J 1999; 17:258–60.
21. Howie VM. Eradication of bacterial pathogens from middle ear infection. Clin Infect Dis 1992; 14(Suppl 2):209–10.
22. Carlin SA, Marchant CD, Shurin PA, Johnson CE, Super DM, Rehmus DIM. Host factors and early therapeutic responses in acute otitis media: does symptomatic response correlate with bacterial outcome? J Pediatr 1991; 118:178–83.
23. Dagan R, Leibovitz E, Greenberg D, Yagupsky P, Fliss DM, Leiberman A. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 1998; 17:776–82.
24. Freid VM, Mukuc DM, Rooks RN. Ambulatory health-care visits by children: principal diagnosis and place of visits. Vital Health Stat 1998; 13:1–23.
25. Long SS, Henretig FM, Teter MJ, McGowen KL. Nasopharyngeal flora and acute otitis media. Infect Immun 1983; 41:987–91.
26. Faden H, Duffy L, Wasielewski R, et al. Relationship between nasopharyngeal colonization and the development of otitis media in children. J Infect Dis 1997; 175:1440–5.
27. Zenni MK, Cheatham SH, Thompson JM, et al. Streptococcus pneumoniae
colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr 1995; 127:533–7.
28. Mastro TD, Ghafoor A, Nomani NK, et al. Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan. Lancet 1991; 337:156–9.
29. Lehmann D, Gratten M, Montgomery J. Susceptibility of pneumococcal carriage isolates to penicillin provides a conservative estimate of susceptibility of invasive pneumococci. Pediatr Infect Dis J 1997; 16:297–305.
30. Lloyd-Evans N, O’Dempsey TJD, Baldeh I, et al. Nasopharyngeal carriage of pneumococci in Gambian children and in their families. Pediatr Infect Dis J 1996; 15:866–71.
31. Gray BM, Converse GM III, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae
in infants: acquisition, carriage and infection during the first 24 months of life. J Infect Dis 1980; 142:923–33.
32. Hodges RG, Macleod CM, Bernhard WG. Epidemic pneumococcal pneumonia: III. pneumococcal carrier studies. Am J Hyg 1946; 44:207–30.
33. Gray BM, Turner ME, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae
in infants: the effects of season and age on pneumococcal acquisition and carriage in the first 24 months of life. Am J Epidemiol 1982; 116:692–703.
34. Hendley JO, Sande MA, Stewart PM, Gwaltney JM. Spread of Streptococcus pneumoniae
in families: carriage rates and distribution of types. J Infect Dis 1975; 132:55–61.
35. Montgomery JM, Lehmann D, Smith T, et al. Bacterial colonization of the upper respiratory tract and its association with acute lower respiratory tract infections in Highland children of Papua New Guinea. Rev Infect Dis 1990; 23:S1006–16.
36. Mastro TD, Nomani NK, Ishaq Z, et al. The use of nasopharyngeal isolates of Streptococcus pneumoniae
and Haemophilus influenzae
from in Pakistan for surveillance for antimicrobial resistance. Pediatr Infect Dis J 1993; 12:824–30.
37. Fredericksen B, Henrichsen J. Throat carriage of Streptococcus pneumoniae
and Streptococcus pyogenes
among infants and children in Zambia. J Trop Pediatr 1988; 34:114–7.
38. Aniansson G, Alm B, Anderson B, et al. Nasopharyngeal colonization during the first year of life. J Infect Dis 1992; 165:S38–42.
39. Bodwell Dunlap M, Stimson Harbery H. Host influence on upper respiratory flora. N Engl J Med 1956; 255:640–6.
40. Loda FA, Collier AM, Glezen WP, Strangert K, Clyde WA Jr, Denny FW. Occurrence of Diplococcus pneumoniae
in the upper respiratory tract of children. J Pediatr 1975; 87:1087–93.
41. Dagan R, Melamed R, Muallem M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996; 174:1352–5.
42. Faden H, Waz MJ, Bernstein JM, et al. Nasopharyngeal flora in the first three years of life in normal and otitis prone children. Ann Otorhinolaryngol 1991; 100:612–15.
43. Invagarsson L, Lundgren K, Ursing J. Bacterial flora in the nasopharynx in healthy children. Acta Otolaryngol 1982; 386:S94–6.
44. Howard AJ, Dunkin KT, Miller GW. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae
in healthy children. Epidemiol Infect 1988; 100:193–203.
45. Harabuchi Y, Faden H, Yamanaka N, et al. Nasopharyngeal colonization with nontypable Haemophilus influenzae
and recurrent otitis media. J Infect Dis 1994; 170:862–6.
46. Faden H, Stanievich J, Brodsky L, Bernstein J, Ogra P. Changes in nasopharyngeal flora during otitis media of childhood. Pediatr Infect Dis J 1990; 9:623–6.
47. Giebink GS. The pathogenesis of pneumococcal otitis media in chinchillas and the efficacy of vaccination in prophylaxis. Rev Infect Dis 1981; 3:342–52.
48. Klugman KP, Koornhof HJ, Kuhnle V. Clinical and nasopharyngeal isolates of unusual multiply resistant pneumococci. Am J Child 1986; 140:1186–90.
49. Geslin P, Buu-Hoi A, Frémaux A, Acar JF. Antimicrobial resistance in Streptococcus pneumoniae
: an epidemiological survey in France, 1970–1990. Clin Infect Dis 1992; 15:95–8.
50. Gehanno P, Olivier C, Boucot I, Lenoir G, Leblanc F, Berche P. Risk factors for nasopharyngeal carriage of resistant S. pneumoniae
[Abstract 160]. In: Proceedings of the 15th Annual Meeting of the European Society for Pediatric Infectious Diseases, Paris, May 22 to 23, 1997.
51. Arason VA, Kristinsson KG, Sigurdsson JA, Stefànsddóttir G, Mölstad S, Gudmundsson. Do antimicrobials increase he carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. Br Med J 1996; 313:387–91.
52. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae
. Clin Infect Dis 1997; 24:356–62.
53. Brook I, Gober AE. Prophylaxis with amoxicillin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacterial from children. Clin Infect Dis 1996; 22:143–5.
54. Abdel-Haq N, Abuhammour W, Asmar B, Thomas R, Dabbagh S, Gonzalez R. Nasopharyngeal colonization with Streptococcus pneumoniae
in children receiving trimethoprim-sulfamethoxazole prophylaxis. Pediatr Infect Dis J 1999; 18:647–9.
55. Dabernat H, Geslin P, Megraud F, et al. Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae
and Haemophilus influenzae
in children with acute otitis media. J Antimicrob Chemother 1998; 41:253–8.
56. Cohen R, Bingen E, Varon E, et al. Change in nasopharyngeal carriage of Streptococcus pneumoniae
resulting from antibiotic therapy for acute otitis media in children. Pediatr Infect Dis J 1997; 16:555–60.
57. Cohen R, Navel M, Grunberg J, et al. One dose ceftriaxone vs.
ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora. Pediatr Infect Dis J 1999; 18:403–9.
58. Dagan R, Leibovitz E, Greenberg D, Yagupsky P, Fliss DM, Leiberman A. Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients. Pediatr Infect Dis J 1998; 17:880–5.
59. Dagan R, Leibovitz E, Piglansky L, Yagupsky P. Effect of antibiotic treatment on pneumococcal nasopharyngeal carriage during and after acute otitis media: comparison of 3 oral drugs [Abstract 1028]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26 to 29, 1999. Washington, DC: American Society for Microbiology, 1999.
60. Melander E, Mölstad S, Persson K, Hansson HB, Söderström M, Ekdahl K. Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae
in children. Eur J Clin Microbiol Infect Dis 1998; 17:834–8.
61. Dagan R, Fraser D, Givon N, Yagupsky P. Coverage of antibiotic-resistant Streptococcus pneumoniae
causing acute otitis media by 7, 9, and 11-valent pneumococcal conjugate vaccines in southern Israel [Abstract 1038]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26 to 29, 1999. Washington, DC: American Society for Microbiology, 1999.
62. Dagan R, Leibovitz E, Cheletz G, Leiberman A, Yagupsky P. Antibiotic treatment in acute otitis media induces middle ear fluid super-infection with pre-existing nasopharyngeal antibiotic-resistant Streptococcus pneumoniae
[Abstract 1183]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26 to 29, 1999. Washington, DC: American Society for Microbiology, 1999.
63. Principi N, Marchisio P, Schito GC, Mannelli S, and the Ascanius Project Collaborative Group. Risk factors for carriage of respiratory pathogens in the nasopharynx of healthy children. Pediatr Infect Dis J 1999; 18:517–23.
64. Ghaffar F, Friedland IR, McCracken GH Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae
. Pediatr Infect Dis J 1999; 18:638–46.
65. Henderson FW, Gilligan PH, Wait K, Goff DA. Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care. J Infect Dis 1988; 157:256–63.
66. Rosén C, Christensen P, Hovelius B, Prellner K. A longitudinal study of the nasopharyngeal carriage of pneumococci as related to pneumococcal vaccination in children attending day-care centers. Acta Otolaryngol 1984; 98:524–32.
67. Givon-Lavi N, Dagan R, Fraser D, Yagupsky P, Porat N. Marked differences in pneumococcal carriage and resistance patterns between day care centers located within a small area. Clin Infect Dis 1999; 29:1274–80.
68. Yaguspky P, Porat N, Fraser D, et al. Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in Southern Israel. J Infect Dis 1998; 177:1003–12.
69. De Lencastre H, Kristinsson KG, Brito-Avô A, et al. Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae
colonization in healthy children attending day care centers in Lisbon, Portugal. Microb Drug Resist 1999; 5:19–29.
Acute otitis media; antibiotic resistance; carriage; pathogens
Copyright © 2000 Wolters Kluwer Health, Inc. All rights reserved.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.
Readers Of this Article Also Read